ReviewMolecular biology reports2025
Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application.
Review in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Multiple myeloma (MM) is a highly heterogeneous plasma cell malignancy characterized by significant immune evasion mechanisms. Its immune microenvironment comprises various immune cells, including dendritic cells (DCs), natural killer (NK) cells, myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs), as well as immunosuppressive factors such as TGF-β and IL-10, which collectively inhibit immune responses. Dysfunctional DCs, impaired NK cell activity and the immunosuppressive effects of MDSCs and Tregs foster tumor cell immune evasion, thereby limiting the efficacy of immunotherapies. In recent years, significant advancements in MM treatment have come from immunotherapy: monoclonal antibodies, chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs) have emerged as key strategies for improving patient outcomes. However, variability in therapeutic efficacy, treatment-related toxicity and the development of resistance remain major obstacles in clinical practice. The MM immune microenvironment, together with tumor cell heterogeneity, complicates treatment and restricts the widespread application and long-term effectiveness of current therapies. To address these challenges, researchers are exploring novel therapeutic targets and integrating gene-editing technologies with immunotherapy to enhance efficacy. The rise of precision medicine and personalized treatment approaches offers further opportunities to optimize therapeutic strategies. Continued progress in MM immunotherapy depends on close collaboration among academia, healthcare institutions, industry and policymakers. Through interdisciplinary cooperation and resource integration, current obstacles can be overcome, accelerating the development and clinical translation of innovative therapies and ultimately providing safer, more effective treatment options for patients.
Indexed as
Identifiers
41335261What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.